Fanconi Anemia, Complementation Group N: Clinical Trials

2 trials for Fanconi Anemia, Complementation Group N, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Recruiting 1
Phase 21Recruiting 1

Follow Fanconi Anemia, Complementation Group N: new trials by email Literature Review of Fanconi Anemia, Complementation Group N trials Research Report on Fanconi Anemia, Complementation Group N

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
DSB2455 - Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Phase 1RecruitingDuke Street Bio Ltd1802024-11-212026-09-02
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Carboplatin, Olaparib - Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2
Phase 2RecruitingVA Office of Research and Development1002019-10-012026-09-17

Narrower conditions

Fanconi Anemia, Complementation Group D1 (2)  ·  Anophthalmia with pulmonary hypoplasia (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)  ·  Prostatic Neoplasms (1)

Broader conditions

Congenital Abnormalities (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Genetic Diseases, Inborn (1)  ·  Genital Diseases (1)  ·  Genital Diseases, Male (1)  ·  Genital Neoplasms, Male (1)  ·  Heredodegenerative Disorders, Nervous System (1)  ·  Male Urogenital Diseases (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Nervous System Diseases (1)  ·  Nervous System Malformations (1)  ·  Neurodegenerative Diseases (1)  ·  Neuromuscular Diseases (1)  ·  Peripheral Nervous System Diseases (1)

Interventions

Carboplatin (1)  ·  olaparib (1)

Sponsors

Duke Street Bio Ltd (1)  ·  VA Office of Research and Development (1)

Countries

United States (2)  ·  France (1)  ·  Hungary (1)  ·  Poland (1)  ·  Spain (1)

Top investigators

Maneesh Jain, MD (1)  ·  Phoebe Tsao, MD MSc (1)  ·  Robert B. Montgomery, MD (1)  ·  Ryan Burri, MD (1)

Results publications

PMID 42843923